<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1900-9607</journal-id>
<journal-title><![CDATA[CES Medicina Veterinaria y Zootecnia]]></journal-title>
<abbrev-journal-title><![CDATA[Ces. Med. Vet. Zootec.]]></abbrev-journal-title>
<issn>1900-9607</issn>
<publisher>
<publisher-name><![CDATA[Universidad CES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1900-96072017000300195</article-id>
<article-id pub-id-type="doi">10.21615/cesmvz.12.3.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia metronómica en el manejo del paciente veterinario con cáncer]]></article-title>
<article-title xml:lang="en"><![CDATA[Metronomic therapy to manage the veterinary patient with cancer]]></article-title>
<article-title xml:lang="pt"><![CDATA[Terapia metronómica no manejo do paciente veterinário com câncer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correal Suárez]]></surname>
<given-names><![CDATA[María Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bortolotti Viera]]></surname>
<given-names><![CDATA[Rafaela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camplesi]]></surname>
<given-names><![CDATA[Annelise Carla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade Estadual Paulista  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Estadual Paulista  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade Estadual Paulista  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>12</volume>
<numero>3</numero>
<fpage>195</fpage>
<lpage>210</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S1900-96072017000300195&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S1900-96072017000300195&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S1900-96072017000300195&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El cáncer es una problemática cada vez más frecuente en la práctica clínica de pequeños animales, para su control se emplean metodologías agresivas con múltiples efectos adversos, lo que ha estimulado la búsqueda de nuevas estrategias terapéuticas. La quimioterapia metronómica consiste en la administración de bajas dosis de fármacos antineoplásicos, en intervalos regulares y por largos períodos de tiempo. Se destaca por su potencial antineoplásico, facilidad de administración y toxicidad reducida, mostrando beneficio clínico en pacientes geriátricos, debilitados o con cáncer avanzado, logrado principalmente a través de la inhibición de la angiogénesis y la modulación inmune antitumoral. En veterinaria, se relata principalmente el uso de ciclofosfamida, clorambucilo o lomustina, asociados en muchos casos con otros fármacos, para el tratamiento de distintos tipos de tumores, con respuestas favorables y baja toxicidad. No obstante, los estudios existentes son limitados y en muchos casos la selección de la posología de administración de los fármacos ha sido empírica, perjudicando su eficacia terapéutica. El objetivo de esta revisión es mostrar la utilidad de este tipo de quimioterapia antineoplásica en animales domésticos, los avances en la comprensión de sus mecanismos de acción, fármacos y esquemas utilizados, así como su potencial tóxico, buscando generar mayor conciencia del médico veterinario al utilizar esta modalidad de quimioterapia en pacientes oncológicos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Cancer is a frequent problem in veterinary practice in small animals; aggre ssive strategies with several side-effects are used to its control, which has stimulated research of new therapeutic options. The metronomic chemotherapy consists in regular administration of low doses of antineoplastic drugs for long periods of time. Together with its antitumor potential, it is administrated easily and has apparent reduced toxicity, showing clinical benefits within advanced diseases or geriatric and weak patients mainly by angiogenesis inhibition and antitumor immune modulation. In small animals, cyclophosphamide, chlorambucil and lomustine have been used mainly, in some cases associated with other drugs, to treat several kinds of tumors, obtaining clinical advantages and low toxicities. However, current studies are limited, and selection of most doses and intervals use to be empirical, in detriment of therapeutic efficacy. This work aims to evidence the potential use of this kind of antineoplastic chemotherapy in domestic animals, as well as the advances in comprehension of its mechanisms of action, drugs, schedules and toxic effects, trying to do a best and more aware use of this chemotherapy strategy in oncologic patients.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo O câncer é um problema cada vez mais comum na rotina clínica de pequenos animais, e para seu controle são utilizadas metodologias agressivas com múltiplos efeitos adversos, o que estimula a busca de novas estratégias terapêuticas. A quimioterapia metronômica consiste na administração de baixas doses de drogas antineoplásicas, em intervalos regulares e por longos períodos de tempo. Chama atenção devido ao por seu potencial anti-neoplásico, facilidade de administração e toxicidade reduzida, mostrando benefício clínico em pacientes geriátricos, debilitados ou com câncer avançado, obtidos principalmente por meio da inibição da angiogênese e da modulação imune antitumoral. Na medicina veterinária, o uso de ciclofosfamida, clorambucil ou lomustina, associado em muitos casos a outras drogas, é relatado principalmente para o tratamento de diferentes tipos de tumores, com respostas favoráveis e baixa toxicidade. No entanto, os estudos existentes são limitados e, em muitos casos, a seleção da posologia da administração das drogas tem sido empírica, prejudicando sua eficácia terapêutica. O objetivo desta revisão é mostrar a utilidade deste tipo de quimioterapia antineoplásica em animais domésticos, os avanços na compreensão de seus mecanismos de ação, fármacos mais indicados e esquemas utilizados, bem como seu potencial tóxico, buscando gerar maior consciência do veterinário ao usar este tipo de quimioterapia em pacientes com câncer.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[dogs]]></kwd>
<kwd lng="en"><![CDATA[low-dose]]></kwd>
<kwd lng="en"><![CDATA[neoplasm]]></kwd>
<kwd lng="en"><![CDATA[oncology]]></kwd>
<kwd lng="es"><![CDATA[dosis baja]]></kwd>
<kwd lng="es"><![CDATA[neoplasia]]></kwd>
<kwd lng="es"><![CDATA[oncología]]></kwd>
<kwd lng="es"><![CDATA[perros]]></kwd>
<kwd lng="es"><![CDATA[quimioterapia]]></kwd>
<kwd lng="pt"><![CDATA[baixa dose]]></kwd>
<kwd lng="pt"><![CDATA[neoplasia]]></kwd>
<kwd lng="pt"><![CDATA[oncologia]]></kwd>
<kwd lng="pt"><![CDATA[cães]]></kwd>
<kwd lng="pt"><![CDATA[quimioterapia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mutsaers]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy: new uses for old drugs]]></article-title>
<source><![CDATA[Vet Clin North Am Small Anim Pract]]></source>
<year>2007</year>
<volume>17</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1079-90</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torimura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Iwamoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Koga]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ueno]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma]]></article-title>
<source><![CDATA[Transl Oncol 20H]]></source>
<year></year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>511-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biller]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy in veterinary patients with cancer]]></article-title>
<source><![CDATA[Vet Clin North Am Small Anim Pract]]></source>
<year>2014</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>817-29</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gnoni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestris]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Licchetta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Santini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scartozzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy from rationale to clinical studies: a dream or reality?]]></article-title>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2015</year>
<volume>95</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>46-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Thamm]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Dow]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Biller]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose cyclophospha-mide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma]]></article-title>
<source><![CDATA[J Vet Intern Med]]></source>
<year>2011</year>
<volume>25</volume>
<page-range>920-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Doloff]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Waxman]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression]]></article-title>
<source><![CDATA[Neoplasia]]></source>
<year>2014</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>84-96</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajasekaran]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy: A relook at its basis and rationale]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>188</volume>
<page-range>128-11</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Argyle]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Veterinary oncology: biology, big data and precision medicine]]></article-title>
<source><![CDATA[Vet J]]></source>
<year>2016</year>
<volume>2H</volume>
<page-range>18-45</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>WHO</collab>
<source><![CDATA[Cancer. Media Centre]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schleis]]></surname>
<given-names><![CDATA[S. E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer screening tests for small animals]]></article-title>
<source><![CDATA[Vet Clin NA Small Anim Pract]]></source>
<year>2014</year>
<volume>44</volume>
<page-range>871-81</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on Genomics in veterinary oncology]]></article-title>
<source><![CDATA[Top Companion Anim Med]]></source>
<year>2009</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>111-21</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanahan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Hallmarks of Cancer]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2000</year>
<volume>100</volume>
<page-range>57-70</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanahan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hallmarks of cancer: The next generation]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2011</year>
<volume>144</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>646-74</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Withrow]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Vale]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Withrow and MacEwen's Small Animal Clinical Oncology]]></source>
<year>2012</year>
<edition>5a ed</edition>
<publisher-name><![CDATA[Saunders Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takimoto]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maximum tolerated dose: clinical endpoint for a bygone era?]]></article-title>
<source><![CDATA[Target Oncol]]></source>
<year>2009</year>
<volume>4</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>141-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanahan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bergers]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bergsland]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2000</year>
<volume>105</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1045-7</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerbel]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Kamen]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The anti-angiogenic basis of metronomic chemotherapy]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2004</year>
<volume>4</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>421-16</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loven]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hasnis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bertolini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Shaked]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer]]></article-title>
<source><![CDATA[Drug Discov Today 20H]]></source>
<year></year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>191-201</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mutsaers]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic Chemotherapy]]></article-title>
<source><![CDATA[Top Companion Anim Med]]></source>
<year>2009</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>117-41</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouche]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Banavali]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Berthold]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Berruti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting. 24-25 June 2014, Milan]]></article-title>
<source><![CDATA[Ecancer Medical Science]]></source>
<year>2014</year>
<volume>8</volume>
<page-range>1-19</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abu Lila]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ishida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy and nanocarrier platforms]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>400</volume>
<page-range>212-42</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin-Padura]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Marighetti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Agliano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Larzabal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts]]></article-title>
<source><![CDATA[Lab Investig]]></source>
<year>2012</year>
<volume>92</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>952-66</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaspar]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Henriques]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marconato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Queiroga]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of low-dose metronomic chemotherapy in dogs - insight into a modern cancer field]]></article-title>
<source><![CDATA[Vet Comp Oncol]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Mancera]]></surname>
<given-names><![CDATA[PFA]]></given-names>
</name>
<name>
<surname><![CDATA[Pinho]]></surname>
<given-names><![CDATA[STR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding the antiangiogenic effect of metronomic chemotherapy through a simple mathematical model]]></article-title>
<source><![CDATA[Physica A]]></source>
<year>2016</year>
<volume>464</volume>
<page-range>251-66</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riesco-Martinez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parra]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saluja]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Francia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Emmenegger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistance to metronomic chemotherapy and ways to overcome it]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>400</volume>
<page-range>111-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Waxman]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modulation of the antitumor activity of metronomic cyclo-phosphamide by the angiogenesis inhibitor axitinib]]></article-title>
<source><![CDATA[Mol Cancer Ther]]></source>
<year>2008</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>79-89</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguirre-Ghiso]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Models, mechanisms and clinical evidence for cancer dormancy]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2007</year>
<volume>7</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>814-46</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ruan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New insights into metronomic chemotherapy-induced immunoregulation]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2014</year>
<volume>154</volume>
<page-range>220-6</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasquier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kavallaris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy: new rationale for new directions]]></article-title>
<source><![CDATA[Nat Rev Clin Oncol]]></source>
<year>2010</year>
<volume>7</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>455-65</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finn]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immuno-oncology: understanding the function and dysfunction of the immune system in cancer]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>8-11</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghiringhelli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Menard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Puig]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Ladoire]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Roux]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic cyclophosphamide regimen selectively depletes CD4 +CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients]]></article-title>
<source><![CDATA[Cancer Immunol Immunother]]></source>
<year>2007</year>
<volume>56</volume>
<page-range>641-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kerbel]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Shaked]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>400</volume>
<page-range>291-104</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De]]></surname>
<given-names><![CDATA[Felice F]]></given-names>
</name>
<name>
<surname><![CDATA[Benevento]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Musella]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Musio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tombolini]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy in head and neck cancer]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>400</volume>
<page-range>219-22</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbolosi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ciccolini]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meille]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Elharrar]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Faivre]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomics chemotherapy: Time for computational decision support. Cancer Chemother]]></article-title>
<source><![CDATA[Pharmacol]]></source>
<year>2014</year>
<volume>74</volume>
<page-range>647-52</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kerbel]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect]]></article-title>
<source><![CDATA[Nat Rev Clin Oncol]]></source>
<year>2016</year>
<volume>13</volume>
<page-range>1-15</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munoz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Shaked]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bertolini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Emmenegger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Man]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy]]></article-title>
<source><![CDATA[Breast]]></source>
<year>2005</year>
<volume>14</volume>
<page-range>466-79</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lien]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Georgsdottir]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sivanathan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Emmenegger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose metronomic chemotherapy: a systematic literature analysis]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>2011</year>
<volume>49</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>3387-95</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaked]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Emmenegger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Man]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cervi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bertolini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangio-genic activity]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2005</year>
<volume>106</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3058-61</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pasquier]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kieran]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Sterba]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shaked]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Baruchel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology]]></article-title>
<source><![CDATA[Transl Oncol]]></source>
<year>2011</year>
<volume>4</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>203-11</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khadka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Akhoon]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy: Low dose less toxic anticancer strategy]]></article-title>
<source><![CDATA[Int J Pharmacol Res]]></source>
<year>2016</year>
<volume>6</volume>
<page-range>195-9</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2014</year>
<volume>349</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>128-15</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Penel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Adenis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?]]></article-title>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2012</year>
<volume>82</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-50</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reagan-Shaw]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nihal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dose translation from animal to human studies revisited]]></article-title>
<source><![CDATA[FASEB J]]></source>
<year>2008</year>
<volume>22</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>659-61</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ledzewicz]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Schattler]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of mathematical models to metronomic chemotherapy: What can be inferred from minimal parameterized models?]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>401</volume>
<page-range>74-80</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic chemotherapy and immunotherapy in cancer treatment]]></article-title>
<source><![CDATA[Cancer Lett]]></source>
<year>2017</year>
<volume>400</volume>
<page-range>282-92</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colleoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rocca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Zorzino]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Masci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose oral metho-trexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2002</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>71-80</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orlando]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cardillo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ghisini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rocca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Balduzzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>225</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Blann]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Payne]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Middleton]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Protheroe]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2011</year>
<volume>104</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1822-7</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Jang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of metronomic chemotherapy with oral cyclophosphamide and methotrexate in patients with non-Hod-gkin lymphoma: a retrospective analysis at a single institution]]></article-title>
<source><![CDATA[Int J Clin Exp Med]]></source>
<year>2016</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>3893-900</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shiraga]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kiwada]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGyla-ted liposomes in a murine solid tumor model]]></article-title>
<source><![CDATA[J Control Release]]></source>
<year></year>
<volume>114</volume>
<page-range>194-200</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lana]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[U'ren]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Plaza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Elmslie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gustafson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs]]></article-title>
<source><![CDATA[J Vet Intern Med]]></source>
<year>2007</year>
<volume>21</volume>
<page-range>764-9</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elmslie]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Glawe]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dow]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas]]></article-title>
<source><![CDATA[J Vet Intern Med]]></source>
<year>2008</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1373-9</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marchetti]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Giorgi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fioravanti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Finotello]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Citi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study]]></article-title>
<source><![CDATA[Invest New Drugs]]></source>
<year>2012</year>
<volume>30</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1725-30</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schrempp]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Childress]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Stewar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Gortari]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma]]></article-title>
<source><![CDATA[J Am Vet Med Assoc]]></source>
<year>2013</year>
<volume>242</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1534-8</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Stell A]]></surname>
<given-names><![CDATA[Borrego J]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez de Merlo E]]></surname>
<given-names><![CDATA[Ruess-Melzer K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia]]></article-title>
<source><![CDATA[J Feline Med Surg]]></source>
<year>2014</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>671-8</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wendelburg]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Price]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Burgess]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Lyons]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-201 2)]]></article-title>
<source><![CDATA[J Am Vet Med Assoc]]></source>
<year>2015</year>
<volume>247</volume>
<page-range>393-403</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Kurzman]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Biller]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Guth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vail]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs]]></article-title>
<source><![CDATA[Vet Comp Oncol]]></source>
<year>2017</year>
<volume>15</volume>
<page-range>421-30</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cancedda]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marconato]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Laganga]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypofractionated radiotherapy for macroscopic canine soft tissue sarcoma: A retrospective study of 50 cases treated with a 5 * 6 Gy protocol with or without metronomic chemotherapy]]></article-title>
<source><![CDATA[Vet Radiol Ultrasound]]></source>
<year>2016</year>
<volume>57</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>75-83</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montagna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cancello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dellapasqua]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Munzone]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Colleoni]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metronomic therapy and breast cancer: a systematic review]]></article-title>
<source><![CDATA[Cancer Treat Rev]]></source>
<year>2014</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>942-50</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Livshits]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An approach to chemotherapy - associated toxicity]]></article-title>
<source><![CDATA[Emerg Med Clin N Am]]></source>
<year>2014</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>167-203</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emmenegger]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Man]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shaked]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Francia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade to-xicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2004</year>
<volume>64</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3994-4000</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jalali]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Hasanzadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Malekinejad]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Achillea millefolium inflorescence aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences]]></article-title>
<source><![CDATA[Chin J Nat Med]]></source>
<year>2012</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>247-54</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Senthilkumar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Devaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Manohar]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Babu]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of squalene on cyclo-phosphamide-induced toxicity]]></article-title>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2005</year>
<volume>364</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>335-42</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viéra]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Correal]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[OS]]></given-names>
</name>
<name>
<surname><![CDATA[Martinato]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[MQP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cistite hemorrágica estéril por uso de ciclofosfamida em cão: relato de caso]]></article-title>
<source><![CDATA[J Bras Ciência An (Anais do Onco in Rio)]]></source>
<year>2016</year>
<volume>S</volume>
<page-range>7-10</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Losurdo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gandini]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Garassino]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Di Tomasso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low-dose 'metronomic chemotherapy' with oral cyclophosphamide and methotrexate in met-astatic breast cancer: a case report of extraordinarily prolonged clinical benefit]]></article-title>
<source><![CDATA[Ecancer Medical Science]]></source>
<year>2012</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kivity]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zafrir]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Loebstein]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pauzner]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mouallem]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>1109-13</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Abed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Orbach]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alla]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Padovani]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pilot study of a pediatric metronomic 4-drug regimen]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2011</year>
<volume>2</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>960-5</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maggo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grover]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Grin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Capecitabine induced colitis]]></article-title>
<source><![CDATA[Pathol - Res Pract]]></source>
<year>2014</year>
<volume>210</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>606-8</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tripp]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Fidel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Patrick]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pratt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerability of metronomic administration of lomustine in dogs with cancer]]></article-title>
<source><![CDATA[J Vet Intern Med]]></source>
<year>2011</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>278-84</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saba]]></surname>
<given-names><![CDATA[Khan S]]></given-names>
</name>
<name>
<surname><![CDATA[Parvez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chaudhari]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats]]></article-title>
<source><![CDATA[Food Chem Toxicol]]></source>
<year>2013</year>
<volume>58</volume>
<page-range>210-9</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Thamm]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Biller]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and immunomodulatory effects of to-ceranib combined with low-dose cyclophosphamide in dogs with cancer]]></article-title>
<source><![CDATA[J Vet Intern Med]]></source>
<year>2012</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>355-62</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
